2. Disease Areas
  3. Infection
  4. Bacterial Infection
  5. Streptococcus Pyogenes Infection

Streptococcus Pyogenes Infection

Streptococcus pyogenes is a Gram-positive, catalase-negative, β-hemolytic facultative anaerobe that causes a wide spectrum of infections in humans, ranging from mild localized conditions such as pharyngitis and impetigo to severe invasive diseases like necrotizing fasciitis and streptococcal toxic shock syndrome. It is a human-specific pathogen primarily colonizing the pharynx, anus, and genital mucosa, with transmission occurring via respiratory droplets, direct contact with infected secretions or lesions, or contaminated surfaces and food. The bacterium's type A antigen, composed of N-acetylglucosamine linked to a rhamnose polymer, contributes to its virulence and immune evasion. Beyond its role in infectious disease, S. pyogenes is being explored for potential applications in cancer immunotherapy due to its ability to stimulate robust immune responses.

Streptococcus Pyogenes Infection (8):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N12586
    Pheophytin a 603-17-8
    Pheophytin a is a multi-target inhibitor, anticancer agent, antioxidant and antiviral agent. Pheophytin a directly binds to and inhibits HCV-NS3/4A protease (IC50=0.89 μM) to block viral replication. Pheophytin a also scavenges free radicals, reduces ferric ions, and exhibits cytotoxic activity against breast cancer cells. Pheophytin a effectively inhibits LPS-induced production of nitric oxide, prostaglandin E2, NOS2 and COX-2, as well as various pro-inflammatory cytokines, by downregulating the transcription levels of inflammatory mediators and blocking the ERK1/2 and STAT-1 pathways. In a low nerve growth factor environment, Pheophytin a also enhances ERK1/2 phosphorylation and synergistically promotes neurite outgrowth through MAPK pathway. Pheophytin a can be used to investigate the pathogenic mechanisms of diseases including chronic hepatitis C, sepsis, breast cancer and Alzheimer's disease.
    Pheophytin a
  • HY-125650
    Pseudouridimycin 1566586-52-4
    Pseudouridimycin (PUM) is an antibiotic that selectively inhibits bacterial RNA polymerase (RNAP), with an IC50 of about 0.1 μM and MICs of 4-6 μg/mL. Pseudouridimycin is a C-nucleoside analogue that's effective against both Gram-negative and Gram-positive bacteria. Pseudouridimycin inhibits bacterial growth in vitro and shows activity in a mouse model of purulent streptococcal peritonitis.
    Pseudouridimycin
  • HY-E70069GL
    Endo S2, Streptococcus pyogenes (GMP Like) 37278-88-9
    Endo S2, Streptococcus pyogenes (GMP Like) is Endo S2, Streptococcus pyogenes (HY-E70069) produced by using GMP like guidelines. Endo-β-N-acetylglucosaminidase (Endo S2) is a key enzyme involved in the processing of free oligosaccharides in the cytosol. Endo-β-N-acetylglucosaminidase catalyzes hydrolysis of N-linked oligosaccharides.
    Endo S2, Streptococcus pyogenes (GMP Like)
  • HY-117845
    Citreamicin alpha 122535-63-1
    Citreamicin alpha (LL-E 19085-alpha) is an antibiotic whose in vitro antimicrobial activity against 429 clinical isolates of Gram-positive cocci has been tested by the agar dilution method. These microorganisms included 313 strains of Staphylococci and 116 strains of Streptococci. The in vitro activity of Citreamicin alpha was compared with that of ampicillin, amoxicillin, ceftriaxone, erythromycin, and vancomycin. For Staphylococci, the MIC values of Citreamicin alpha ranged from 0.12-4.0 μg/ml, and for Streptococcus pyogenes of the genus Streptococcus, it was 0.03-0.12 μg/ml. However, enterococci were relatively resistant, requiring 2.0 μg/ml of the agent to inhibit 64% of the 62 tested strains. The in vitro activity of this antibiotic was much better than that of ampicillin, amoxicillin, ceftriaxone, and erythromycin, but comparable or slightly inferior to that of vancomycin.
    Citreamicin alpha
  • HY-119555
    Nifurpipone 24632-47-1
    Nifurpipone is an orally active broad-spectrum antimicrobial agent. Nifurpipone acts against Gram-positive and Gram-negative bacteria, and reduces bacterial loads in systemic, intramuscular and urinary tract infections in mouse models. Nifurpipone can be used in studies related to bacterial infections.
    Nifurpipone
  • HY-W653770
    Desmycosin 11032-98-7
    Desmycosin is a macrolide antibiotic. Desmycosin exhibits biological activity against H. influenzae, S.aureus, S. pneumoniae, and S. pyogenes with MIC values of 4, 1, <0.125, and <0.125 µg/ml, respectively. Desmycosin is an acidic degradation product of tylosin.
    Desmycosin
  • HY-174499
    Cas9 Nickase D10A mRNA (5moU)
    Cas9 Nickase D10A mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9) that contains a D10A amino acid substitution. This mRNA also contains a C-terminal nuclear localization signal followed by a HA tag.Cas9 functions as part of the CRISPR (clustered regularly interspaced short palindromic repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform the DNA cleavage. While wild-type Cas9 creates a double-stranded break at the target site, Cas9 nickase creates a single-stranded break. This favors homology-directed repair and decreases the occurrence of non-homologous end joining.
    Cas9 Nickase D10A mRNA (5moU)
  • HY-125650A
    Pseudouridimycin TFA 2760807-99-4
    Pseudouridimycin (PUM) TFA is an antibiotic that selectively inhibits bacterial RNA polymerase (RNAP), with an IC50 of about 0.1 μM and MICs of 4-6 μg/mL. Pseudouridimycin TFA is a C-nucleoside analogue that's effective against both Gram-negative and Gram-positive bacteria. Pseudouridimycin TFA inhibits bacterial growth in vitro and shows activity in a mouse model of purulent streptococcal peritonitis.
    Pseudouridimycin TFA